These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38823512)

  • 1. Prevention of exercise-induced anaphylaxis by ibrutinib.
    Callisto A; Perkins GB; Troelnikov A; Mhatre S; Hissaria P; Smith W
    J Allergy Clin Immunol Pract; 2024 Sep; 12(9):2503-2505.e2. PubMed ID: 38823512
    [No Abstract]   [Full Text] [Related]  

  • 2. Characterization of zanubrutinib safety and tolerability profile and comparison with ibrutinib safety profile in patients with B-cell malignancies:
    Brown JR; Ghia P; Jurczak W; Kahl BS; Lamanna N; Robak T; Shadman M; Tam CS; Qiu L; Paik J; Salmi T; Wang L; Zhang J; Zhang M; Cohen A; Ma H; Tedeschi A
    Haematologica; 2024 Jul; 109(7):2277-2283. PubMed ID: 38426293
    [No Abstract]   [Full Text] [Related]  

  • 3. Infection with ibrutinib in patients with chronic lymphocytic leukemia: How strong is the association?
    Ball S; Vutthikraivit W; Maiti A; Short NJ
    Eur J Haematol; 2018 Sep; 101(3):418-420. PubMed ID: 29791043
    [No Abstract]   [Full Text] [Related]  

  • 4. Psoriasis: a new adverse event of ibrutinib.
    Rapparini L; Massi A; Baraldi C; Gugliotta G; Pileri A
    Ital J Dermatol Venerol; 2024 Apr; 159(2):205-207. PubMed ID: 38287741
    [No Abstract]   [Full Text] [Related]  

  • 5. Cardiovascular events reported in patients with B-cell malignancies treated with zanubrutinib.
    Moslehi JJ; Furman RR; Tam CS; Salem JE; Flowers CR; Cohen A; Zhang M; Zhang J; Chen L; Ma H; Brown JR
    Blood Adv; 2024 May; 8(10):2478-2490. PubMed ID: 38502198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trisomy 12 is associated with an abbreviated redistribution lymphocytosis during treatment with the BTK inhibitor ibrutinib in patients with chronic lymphocytic leukaemia.
    Thompson PA; Ferrajoli A; O'Brien S; Wierda WG; Keating MJ; Burger JA
    Br J Haematol; 2015 Jul; 170(1):125-8. PubMed ID: 25522014
    [No Abstract]   [Full Text] [Related]  

  • 7. Zanubrutinib for the treatment of Waldenström Macroglobulinemia.
    Lim KJC; Tam CS
    Expert Rev Hematol; 2020 Dec; 13(12):1303-1310. PubMed ID: 33297772
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparative Analysis of Risk Prediction Scores for Treatment-Emergent Atrial Fibrillation Among Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib.
    Babbili A; Lakra R; Thotamgari SR; Gaddam SJ; Grewal US; Dominic P
    Am J Ther; 2024 Jul-Aug 01; 31(4):e453-e455. PubMed ID: 38305826
    [No Abstract]   [Full Text] [Related]  

  • 9. Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies.
    Xu L; Shadman M; Flinn IW; Levy MY; Porter R; Burke JM; Zafar SF; Cultrera JL; Misleh J; Kingsley EC; Yimer HA; Freeman B; Chaudhry A; Tumula PK; Gandhi MD; Crescenzo R; By K; Cohen A; Chen DY; Idoine A; Manda S; Sharman JP; Ramakrishnan V
    Haematologica; 2024 Jul; 109(7):2284-2289. PubMed ID: 38268449
    [No Abstract]   [Full Text] [Related]  

  • 10. Pirtobrutinib in relapsed or refractory CLL and SLL.
    Woyach JA
    Clin Adv Hematol Oncol; 2024 Jun; 22(5):230-231. PubMed ID: 38805315
    [No Abstract]   [Full Text] [Related]  

  • 11. Ibrutinib-Induced Skin Rash.
    Kirar S; Gogia A; Gupta R; Mallick S
    Turk J Haematol; 2021 Feb; 38(1):81-83. PubMed ID: 33053966
    [No Abstract]   [Full Text] [Related]  

  • 12. Ibrutinib-Induced Cardiac Tamponade in Chronic Lymphocytic Leukemia.
    Kidoguchi K; Kubato Y; Nishimura Y; Kizuka-Sano H; Kimura S
    Turk J Haematol; 2021 Feb; 38(1):83-85. PubMed ID: 33161683
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Coutre SE; Byrd JC; Hillmen P; Barrientos JC; Barr PM; Devereux S; Robak T; Kipps TJ; Schuh A; Moreno C; Furman RR; Burger JA; O'Dwyer M; Ghia P; Valentino R; Chang S; Dean JP; James DF; O'Brien SM
    Blood Adv; 2019 Jun; 3(12):1799-1807. PubMed ID: 31196847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zanubrutinib: a novel BTK inhibitor in chronic lymphocytic leukemia and non-Hodgkin lymphoma.
    Tam CS
    Clin Adv Hematol Oncol; 2019 Jan; 17(1):32-34. PubMed ID: 30843894
    [No Abstract]   [Full Text] [Related]  

  • 15. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes.
    Cheah CY; Chihara D; Romaguera JE; Fowler NH; Seymour JF; Hagemeister FB; Champlin RE; Wang ML
    Ann Oncol; 2015 Jun; 26(6):1175-1179. PubMed ID: 25712454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis B Virus Reactivation under Ibrutinib Treatment in a Patient with Chronic Lymphocytic Leukemia.
    İskender G; İskender D; Ertek M
    Turk J Haematol; 2020 Aug; 37(3):208-209. PubMed ID: 32248674
    [No Abstract]   [Full Text] [Related]  

  • 17. Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial.
    Bartlett NL; Costello BA; LaPlant BR; Ansell SM; Kuruvilla JG; Reeder CB; Thye LS; Anderson DM; Krysiak K; Ramirez C; Qi J; Siegel BA; Griffith M; Griffith OL; Gomez F; Fehniger TA
    Blood; 2018 Jan; 131(2):182-190. PubMed ID: 29074501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypertension treatment for patients receiving ibrutinib: a multicenter retrospective study.
    Samples L; Voutsinas J; Fakhri B; Khajavian S; Spurgeon S; Stephens D; Skarbnik A; Mato A; Broome C; Gopal A; Smith S; Lynch R; Rainey M; Kim MS; Barrett-Campbell O; Hemond E; Tsang M; Ermann D; Malakhov N; Rao D; Shakib-Azar M; Morrigan B; Chauhan A; Plate T; Gooley T; Ryan K; Lansigan F; Hill B; Pongas G; Parikh SA; Roeker L; Allan JN; Cheng R; Ujjani C; Shadman M
    Blood Adv; 2024 May; 8(9):2085-2093. PubMed ID: 38315043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials.
    O'Brien SM; Jaglowski S; Byrd JC; Bannerji R; Blum KA; Fox CP; Furman RR; Hillmen P; Kipps TJ; Montillo M; Sharman J; Suzuki S; James DF; Chu AD; Coutre SE
    JAMA Oncol; 2018 May; 4(5):712-716. PubMed ID: 29470582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Hillmen P; Brown JR; Eichhorst BF; Lamanna N; O'Brien SM; Qiu L; Salmi T; Hilger J; Wu K; Cohen A; Huang J; Tam CS
    Future Oncol; 2020 Apr; 16(10):517-523. PubMed ID: 32207333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.